01
Cash & equivalents increased 95.8%
Cash & equivalents changed +95.8% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$2.0M→$3.9MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTORAGENICS INC's latest supported as-filed period reports revenue of $37,653. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +95.8% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Net income changed -11.3% from the comparable as-filed period.
Operating income changed -51.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
OGEN · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001493152-26-037749SEC ↗4Jul 7, 2026Period Jul 1, 20260002144116-26-000005SEC ↗8-KJul 6, 2026Period Jun 29, 20260001493152-26-032155SEC ↗8-KMay 19, 2026Period May 18, 20260001493152-26-024363SEC ↗10-QMay 8, 2026Period Mar 31, 20260001493152-26-021967SEC ↗8-KMay 7, 2026Period May 7, 20260001493152-26-021627SEC ↗8-KApr 13, 2026Period Apr 13, 20260001493152-26-016294SEC ↗8-KTransaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 1, 2026Filed Jul 7, 2026 | Spencer JohnChief Financial Officer | Grant Or AwardDirect | 55,900 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +161.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001493152-26-014128